Innate Pharma S.A. is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether certain statements by Innate Pharma S.A. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
France based Innate Pharma S.A., a clinical-stage biotechnology company, discovers and develops therapeutic antibodies for the treatment of cancer in France and internationally. Innate Pharma S.A. reported that its annual Total Revenue rose from $32.63 million in 2017 to $79.89 million in 2018, and that its Net Loss of $48.01 million in 2017 turned to a Net Income of $3.04 million in 2018.
On January 9, 2020, Innate Pharma S.A. announced its decision “to suspend enrollment of new patients” in its TELLOMAK Phase II trial evaluating the efficacy and safety of lacutamab (IPH4102) in patients with advanced T-cell lymphomas. Innate cited “ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company’s manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials.”
Shares of Innate Pharma S.A. (NASDAQ: IPHA) declined from $8.24 per share on January 2, 2020 to as low as $6.70 per share on January 9, 2020
Those who purchased shares of Innate Pharma S.A. (NASDAQ: IPHA) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
